Sex and androgenic steroid receptor expression in hepatic adenomas

Abstract

Sex hormones and anabolic-androgenic steroids are implicated in the development and progression of hepatic adenomas (HA). We studied the expression of their receptors in HA and adjacent liver. Archival tissue sections of 27 HA (16 resections, four needle biopsies, seven aspirations) from 18 patients, and the adjacent liver, were immunostained with monoclonal antibody to estrogen receptor (ER, 1 80 ) (Dako, Carpinteria, CA), progesterone receptor (PR, 1 50 ) (BioGenex, San Ramon, CA), and androgen receptor (AR, 1 80 ) (BioGenex). An avidin-biotin complex technique was used with microwave antigen retrieval. Nuclear expression was assessed as 1 + to 3+ intensity, with semiquantitation of the percentage of nuclei immunopositive. Five percent or more nuclei immunopositive was regarded as positive. The 18 patients included 16 females of 34 years mean age (range, 16 to 49) with an available history of oral contraceptives in five; the two men were 24 and 30 years, with no history of androgenic steroids. ER, PR, and AR were present in seven (26%) (1 ± 2+ intensity, 5% to 10% of nuclei) of HA, seven (26%) (1 ± 2+ intensity, 5% to 30% of nuclei) and nine (33%) (1 ± 3+ intensity, 5% to 80% of nuclei), respectively. In the adjacent liver in 11 cases, there were one (9%) ER, (2+ intensity, 5% of nuclei), four (36%) PR (1 ± 2+ intensity, 5% to 20% of nuclei), and two (18%) AR (2 ± 3+ intensity, 10% of nuclei). Receptors are present and may mediate the action of sex hormones or androgenic steroids on HA and adjacent liver, but in less than one third of patients. This may have therapeutic implications.